Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 442Rectal Neoplasms 209Colonic Neoplasms 202Pancreatic Neoplasms 133Stomach Neoplasms 117Neoplasm Metastasis 97Neoplasms 64Esophageal Neoplasms 57Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Lymphoma 49Leukemia 41Carcinoma, Hepatocellular 41Adenocarcinoma Of Esophagus 37Burkitt Lymphoma 33Adenocarcinoma 29Cholangiocarcinoma 27Biliary Tract Neoplasms 23Carcinoma, Non-Small-Cell Lung 21Gastrointestinal Neoplasms 20Gallbladder Neoplasms 20Lymphoma, Non-Hodgkin 19Esophageal Squamous Cell Carcinoma 15Osteosarcoma 14Liver Neoplasms 14Bile Duct Neoplasms 14Unspecified Adult Solid Tumor, Protocol Specific 13Lymphoma, Large B-Cell, Diffuse 13Leukemia, Biphenotypic, Acute 13Ovarian Neoplasms 12Leukemia, Myeloid, Acute 12

Interventions

Bevacizumab 5pembrolizumab 4Gemcitabine 4Cisplatin 4napabucasin 3Paclitaxel 3Irinotecan 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3lenvatinib 2entinostat 2anlotinib 2Taxes 2Sunitinib 2Sorafenib 2Radiotherapy, Intensity-Modulated 2Ocoxin 2Leucovorin 2Immunotherapy 2Fluorouracil 2Carboplatin 2vorasidenib 1sipuleucel-T 1pralsetinib 1palbociclib 1olaparib 1niraparib 1luprolide acetate gel depot 1linifanib 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms, Glandular and Epithelial × Leucovorin × Clear all
NCT02753127 2023-11-15

CanStem303C

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,253 enrolled 18 charts
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Colorectal Neoplasms

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡